Electromed Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Jim Cunniff
Chief Executive Officer (CEO)
US$1.5m
Compensación total
| Porcentaje del salario del CEO | 34.93% |
| Permanencia del CEO | 2.9yrs |
| Participación del CEO | 1.8% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 6.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • Jun 02
ELMD: Bronchiectasis Exposure And Margin Execution Will Support Future Upside
Analysts have nudged their price target on Electromed stock higher to $40 from $38, citing record Q3 results with 18.4% revenue growth, strong operating leverage, and confidence in continued double-digit expansion supported by broader adoption, payer coverage, and an underpenetrated bronchiectasis market. What's in the News Analysts raised their price target on Electromed stock to $40 from $38, citing record Q3 results and 18.4% revenue growth.
Actualización de narrativa • Apr 18
ELMD: Refined Discount Rate And P/E Assumptions Will Drive Future Upside
Analysts raised their price target on Electromed by $2, reflecting updated assumptions about the discount rate, profit margin, revenue growth, and future P/E that support a slightly higher valuation framework. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rate and future P/E that leave room for upside if execution stays on track.Actualización de narrativa • Apr 04
ELMD: Refreshed Discount Rate And P/E Assumptions Will Support Future Upside
Analysts have raised their price target on Electromed by $2, citing updated assumptions about discount rates, revenue growth, profit margins and future P/E that support a slightly higher fair value estimate. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rates and future P/E, which together suggest more support for the current valuation than before.Actualización de narrativa • Mar 21
ELMD: Share Repurchases And Margin Execution Will Support Future Upside
Analysts have raised their price target on Electromed by $2 to reflect updated assumptions around revenue growth, profit margin and long-term P/E expectations. Analyst Commentary Recent research points to a more cautious tone around Electromed, even alongside the higher price target.Actualización de narrativa • Mar 06
ELMD: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have increased their price target on Electromed by $2 to $36, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as key factors behind the change. Analyst Commentary While the new US$36 price target reflects updated valuation work, some bearish analysts are still flagging risk factors that they believe limit upside for Electromed at current levels.Actualización de narrativa • Feb 20
ELMD: Share Repurchases Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target on Electromed up by $1 to $37, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E after the latest Street research. Analyst Commentary Recent Street research has focused on how Electromed's fundamentals line up with the revised fair value assumptions and the updated $37 target.Actualización de narrativa • Feb 06
ELMD: Completed Share Buyback Will Support Future Upside In Undervalued Shares
Analysts have adjusted their price target on Electromed to reflect a fair value of $36.00, citing only minor tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E. Their overall valuation view remains largely unchanged.Actualización de narrativa • Jan 21
ELMD: Share Buyback And Higher Margin Outlook Will Support Future Upside
Analysts have kept their price target for Electromed steady at US$34.00, reflecting updated views on slightly higher projected revenue growth and profit margins, along with a marginally adjusted discount rate and future P/E assumption. What's in the News Completed the repurchase of 40,848 shares, representing 0.49% of the company, for US$1 million under the share buyback announced on September 9, 2025 (Key Developments).Actualización de narrativa • Jan 07
ELMD: Higher Margin Outlook And Share Buyback Will Support Upside Potential
Analysts have raised their fair value estimate for Electromed from US$29 to US$34, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Between September 9, 2025 and September 30, 2025, Electromed repurchased 40,848 shares for US$1 million, representing 0.49% of shares.Actualización de narrativa • Dec 15
ELMD: Share Repurchase Program Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target for Electromed slightly higher to approximately $36.00 per share, citing modest improvements in discount rate assumptions and forward valuation metrics while largely reaffirming their prior outlook. What's in the News Completed a share repurchase tranche totaling 40,848 shares, or about 0.49 percent of outstanding shares, for approximately $1 million under the buyback program announced September 9, 2025 (company filing) Valuation Changes Fair Value Estimate reaffirmed at approximately $36.00 per share, reflecting no material change in intrinsic value assumptions.Actualización de narrativa • Nov 30
ELMD: Share Repurchase Plan And Expanding Outlook Will Lift Share Price
Analysts have raised their price target for Electromed from $35.25 to $36.00. They cite an improved outlook for future revenue growth, despite a slightly higher discount rate and marginally lower profit margin projections.Actualización de narrativa • Nov 16
ELMD: Double-Digit Revenue Gains And Buybacks Will Drive Shares Higher
Electromed's analyst fair value target increased slightly from $35.00 to $35.25, as analysts cite consistent double-digit revenue growth forecasts and improving operational efficiency in recent reports. Analyst Commentary Bullish Takeaways Bullish analysts highlight Electromed's consistent double-digit revenue growth forecasts and note that ongoing top-line expansion is expected in the coming years.
Nueva narrativa • Feb 21
The Triple Down On Bronchiectasis Campaign Will Expand SmartVest Clearway's Market Reach
Diversifying beyond homecare and investing in sales efforts may drive revenue growth and improve earnings through expanded market channels and effective sales execution.Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$10m |
| Dec 31 2025 | n/a | n/a | US$9m |
| Sep 30 2025 | n/a | n/a | US$8m |
| Jun 30 2025 | US$1m | US$519k | US$8m |
| Mar 31 2025 | n/a | n/a | US$7m |
| Dec 31 2024 | n/a | n/a | US$7m |
| Sep 30 2024 | n/a | n/a | US$6m |
| Jun 30 2024 | US$3m | US$500k | US$5m |
Compensación vs. Mercado: La compensación total de Jim($USD1.49M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.59M).
Compensación vs. Ingresos: La compensación de Jim ha sido consistente con los resultados de la empresa en el último año.
CEO
Jim Cunniff (60 yo)
2.9yrs
Permanencia
US$1,486,329
Compensación
Mr. James L. Cunniff, also known as Jim, serves as an Independent Director at Avanos Medical Inc. since April 21, 2026. He serves as the President and Chief Executive Officer at Electromed, Inc., since Jul...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.6yrs | US$1.49m | 1.78% $ 5.4m | |
| Independent Director | 6.8yrs | US$141.34k | 0.25% $ 771.1k | |
| Chairman | 12.6yrs | US$158.84k | 0.43% $ 1.3m | |
| Independent Director | 3.9yrs | US$136.34k | 0.11% $ 330.5k | |
| Lead Independent Director | 4.6yrs | US$166.84k | 0.18% $ 550.8k | |
| Independent Director | 5.6yrs | US$139.34k | 0.22% $ 661.0k | |
| Independent Vice Chairman of the Board | 11.6yrs | US$144.34k | 0.47% $ 1.4m | |
| Independent Director | 4.6yrs | US$134.34k | 0.18% $ 550.8k | |
| Member of Bronchiectasis Advisory Board | 8.8yrs | sin datos | sin datos | |
| Member of Bronchiectasis Advisory Board | 8.8yrs | sin datos | sin datos | |
| Member of Bronchiectasis Advisory Board | 8.8yrs | sin datos | sin datos |
6.8yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de ELMD se considera experimentada (6.8 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/05 01:16 |
| Precio de las acciones al final del día | 2026/06/05 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Electromed, Inc. está cubierta por 6 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Ilya Zubkov | Freedom Broker |